Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
  • Patent number: 11001833
    Abstract: A combined ribosome-display and phage-display method and kit for carrying out the method are provided. The method includes screening a ribosome-display library of binding agents to identify binding agents that interact with one or more target molecules of interest, converting the RNA encoding the binding agents to a phage-display format by amplification and primer extension, and the screening the phage-display library to enrich for binding agents that interact with one or more target molecules of interest.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 11, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Michael Kierny, Brian Kay
  • Patent number: 10995326
    Abstract: Provided is a method for safely and selectively producing a substrate culture product including a large amount of a desired degrading enzyme. A method for producing a substrate culture product used for feedstuff includes inoculating filamentous fungi bred so that a target degrading enzyme is produced by self-cloning in high productivity on a substrate, and producing the substrate culture product having functionality by ventilating the substrate to carry out solid culture.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 4, 2021
    Assignee: FUJIWARA TECHNO-ART CO., LTD.
    Inventors: Masahiro Kariyama, Akira Mori, Satoko Takahashi
  • Patent number: 10995347
    Abstract: The invention provides methods for improving efficiency of fermentation by arginine supplementation, and genetically modified bacterium for use therefor. More particularly the invention provides methods for (i) increasing the production ATP intensive products with arginine supplementation, (ii) increasing utilization of arginine by a C1-fixing bacterium; and (iii) providing C1-fixing bacterium with optimized arginine de-aminase pathways.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: May 4, 2021
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, James Bruce Yarnton Haycock Behrendorff, Kaspar Valgepea, Esteban Marcellin, Lars K. Nielsen, Renato de S.P. Lemgruber
  • Patent number: 10994047
    Abstract: Peptide dendrimers and agents are described, which can be used for polymerising fibrinogen and as haemostatic agents. The peptide dendrimers comprise a branched core, and a plurality of fibrinogen-binding peptides separately covalently attached to the branched core.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: May 4, 2021
    Assignee: HAEMOSTATIX LIMITED
    Inventor: Renata Zbozien
  • Patent number: 10988730
    Abstract: The invention relates to a lyophilisate or to a powder including i) at least one globin, a globin protomer or an extracellular hemoglobin from annelids, and ii) at least one biological material from annelids that is different from said globin, from said protomer and from said hemoglobin.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 27, 2021
    Assignee: Hemarina
    Inventor: Franck Zal
  • Patent number: 10987369
    Abstract: A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: April 27, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Wen-Chin Yang, Lee-Tian Chang
  • Patent number: 10982222
    Abstract: Provided are isolated polynucleotides, polypeptides encoded thereby, nucleic acid constructs comprising same, plant cells and plants comprising same and methods of generating plants with increased yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, abiotic stress tolerance, and/or nitrogen use efficiency, wherein the polynucleotides encode polypeptides at least 80% identical to SEQ ID NO: 574-930, 6266-10549 or 10550, such as the polynucleotides set forth in SEQ ID NOs:1-573, and 931-6265.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 20, 2021
    Assignee: Evogene Ltd.
    Inventors: Limor Poraty-Gavra, Ilya Pankratov, Hagai Karchi
  • Patent number: 10982250
    Abstract: A method of reducing glycation of an amino acid in a protein produced by a host cell in cell culture medium is disclosed.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: April 20, 2021
    Assignee: Genentech, Inc.
    Inventors: Inn Huam Yuk, Bradley Richard Snedecor, Dana Christian Andersen
  • Patent number: 10980870
    Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 20, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Matthew P. Morrow
  • Patent number: 10982242
    Abstract: The present invention relates to an optimized fermentation process of coenzyme Q10, particularly to a fermentation process of coenzyme Q10 via flow feeding based on cooperative control of changes of online oxygen consumption rate and conductivity. During the fermentation process of coenzyme Q10 production strains, the oxygen consumption rate is controlled between 30-150 mmol/L·h and the conductivity is maintained between 3.0-30.0 ms/cm via flow feeding, so as to facilitate strain growth and the start of coenzyme Q10 synthesis and accumulation. The present invention can substantially increase output of coenzyme Q10 and greatly reduce the production cost with simple process control and strong operability, thus being applicable to large-scale industrial production.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 20, 2021
    Assignees: SHANGYU NHU BIOLOGICAL CHEMICAL CO., LTD., ZHEJIANG UNIVERSITY, ZHEJIANG NHU COMPANY LTD.
    Inventors: Hongwei Yu, Yong Lv, Yong Li, Jianbo Chen, Shaofeng Chen, Weifeng Li, Hongmei Zhang, Yongqiang Zhu
  • Patent number: 10973908
    Abstract: A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Inventor: David Gordon Bermudes
  • Patent number: 10975382
    Abstract: Provided are isolated polynucleotides comprising a nucleic acid sequence at least 80% identical to SEQ ID NO:619, 617, 606, 615, 629, 1-36, 40, 41, 43-45, 49, 52-56, 58, 113-343, 351, 354-358, 605, 607-614, 616, 618, 620-628, 630-638, 642, 645, 650, 651, 670, or 671. Also provided are nucleic acid constructs comprising same, isolated polypeptides encoded thereby, transgenic cells and transgenic plants comprising same and methods of using same for increasing abiotic stress tolerance, yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, and/or nitrogen use efficiency of a plant.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 13, 2021
    Assignee: Evogene Ltd.
    Inventors: Sharon Ayal, Eyal Emmanuel, Zur Granevitze, Alex Diber, Basia Judith Vinocur, Hagai Karchi, Yoav Herschkovitz
  • Patent number: 10975131
    Abstract: Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen infections.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: April 13, 2021
    Assignee: University of Massachusetts
    Inventors: Sanjay Ram, Douglas T. Golenbock, Alberto Visintin, Jutamas Shaughnessy
  • Patent number: 10968322
    Abstract: The present invention relates to an additive or additive composition for improved production of fermentable sugars from lignocellulosic biomass during enzymatic hydrolysis. More particularly, the present invention discloses petrochemical waste as an additive or an additive composition containing one or more ethylene glycol oligomers and one or more metal ions which are useful for improved production of fermentable sugars from lignocellulosic biomass during enzymatic hydrolysis.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 6, 2021
    Assignees: INDIAN OIL CORPORATION LIMITED, DEPARTMENT OF BIOTECHNOLOGY
    Inventors: Alok Satlewal, Ruchi Agrawal, Ravindra Kumar, Anshu Shanker Mathur, Ravi Prakash Gupta, Biswajit Basu, Deepak Kumar Tuli
  • Patent number: 10962539
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • Patent number: 10954307
    Abstract: Products, compositions, and methods for using one or more small particles to facilitate the delivery of one or more antihistamines to a human body are disclosed. In some aspects, methods are disclosed that utilize small particles that may be integrated with one or more guiding antibodies that detect and bind to high affinity immunoglobulin E receptors associated with various types of target cells, such as mast cells, basophils, and dendritic cells. Methods in accordance with the present disclosure may use small particles that are configured to contain relatively high concentrations of at least one form of at least one antihistamine and deliver the antihistamine(s) to areas within a human body where one or more actions associated with an allergic reaction may be in progress and/or where one or more actions associated with an allergic reaction may be likely to occur.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 23, 2021
    Assignee: LIPIDAIR, LLC
    Inventors: Michael Dale Kahil, Tawanda Gumbo
  • Patent number: 10953106
    Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: March 23, 2021
    Assignee: LONZA LTD
    Inventors: Ramon Gomez De La Cuesta, Jesús Zurdo, Lars Arne Andreas Arnell, Laurent Ducry, Laurence Bonnafoux
  • Patent number: 10941419
    Abstract: The present invention relates to the production of aromatic hexanols and compositions containing them. In particular provided herein are methods of producing hexenols comprising: a) contacting a hydroperoxide of a polyunsaturated fatty acid with a modified hydroperoxide lyase to form a hexenal; and b) reducing the hexenal to a hexenol in the presence of a hydride donor, a ketoreductase, and a co-factor wherein the contacting and reducing steps are carried out at essentially the same time in the substantial absence of baker's yeast.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 9, 2021
    Assignee: Firmenich SA
    Inventors: Fredi Bruhlmann, Rebecca Buller
  • Patent number: 10941178
    Abstract: The present disclosure relates generally to methods of producing, processing, or purifying antibodies. The present disclosure also relates to methods of producing, processing, or purifying a target antibody from cell cultures to remove host cell proteins.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 9, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Nooshafarin Sanaie, Brian Kluck, Andrew Quezada, Robert vonder Reith, Chi Tran, James Woo
  • Patent number: 10932482
    Abstract: In some embodiments, the present disclosure relates to an avian-free egg white composition including 45-63% Ovalbumin, 9-15% Ovotransferrin, 0-15% Ovomucoid, 3-5% Ovoglobulin G2, 3-5% Ovoglobulin G3, 2.5-5% Ovomucin, 3-5% Lysozyme, 1-2% Ovoinhibitor, 0.8-1.5% Ovoglycoprotein, 0.6-1.0% Flavoprotein, 0.3-0.8% Ovomacroglobulin, 0.02-0.1% Avidin, and 0.02-0.1% Cystatin. In some embodiments, the composition includes an edible yeast and one or more of the preceding proteins. In some embodiments, the avian-free egg white further includes one or more of: flavor enhancers, calcium supplements, added vitamins, and a gelling agent. In some embodiments, the present disclosure pertains to a non-allergenic egg-white composition for human consumption. In some embodiments, the present disclosure pertains to methods of making the avian-free egg-white composition.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 2, 2021
    Inventor: Kedarnath Krishnamurthy Challakere
  • Patent number: 10934329
    Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: March 2, 2021
    Assignee: California Institute of Technology
    Inventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
  • Patent number: 10927399
    Abstract: The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 23, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ulrike Maria Mueller, Liang Wu, Lourina Madeleine Raamsdonk, Aaron Adriaan Winkler
  • Patent number: 10927164
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 23, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild
  • Patent number: 10920204
    Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having one or more modifications as compared to a parent lipolytic enzyme having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 16, 2021
    Assignee: DANISCO US INC
    Inventors: Ayrookaran J. Poulose, Thomas P. Graycar, Sina Pricelius, David A. Estell
  • Patent number: 10921309
    Abstract: A bioinspired protein pore-based nanostructure that can provide selective, real-time sampling of protein-protein interactions at single-molecule resolution. This modular nanostructure relied on a single polypeptide chain that encompassed a heavily truncated outer membrane protein, a highly flexible connector, a protein receptor element, as well as a polypeptide adapter. The presence of a protein ligand analyte in solution produced reversible binding and release events, in the form of discrete and stochastic current transitions between open substates of the transmembrane pore, the nature of which depend on both the amount of protein ligand analyte and the strength of the transient PPIs in aqueous phase.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: February 16, 2021
    Assignee: SYRACUSE UNIVERSITY
    Inventors: Liviu Movileanu, Avinash Kumar Thakur
  • Patent number: 10918739
    Abstract: The present disclosure discloses a human sDR5-Fc fusion protein in the preparation of adjuvant therapy for myocardial ischemia-reperfusion injury. The sDR5-Fc antibody fusion protein of the disclosure is prepared by connecting the 182 amino acids in DR5 extracellular domain with the human anti-Fc fragments. It has been tested that the sDR5-Fc antibody fusion protein of the disclosure can basically avoid Fc-mediated ADCC effect and can significantly reduce the area of myocardial infarction in rats of myocardial ischemia-reperfusion models.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 16, 2021
    Assignee: Suzhou Yongxin Biological Science and Technology Co., Ltd
    Inventor: Yuanfang Ma
  • Patent number: 10914736
    Abstract: The present invention relates to a nanovesicle comprising a heterodimeric G-protein coupled receptor, a method for preparing the nanovesicle, a field effect transistor-based taste sensor comprising the nanovesicle, and a method for manufacturing the taste sensor. The field effect transistor based taste sensor functionalized by the nanovesicle comprising the heterodimer G-protein coupled receptor according to the present invention has excellent sensitivity and selectivity and may highly specifically detect a sweet taste substance in real time, by using the heterodimeric G-protein coupled receptor and the nanovesicle comprising the same.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 9, 2021
    Assignee: Seoul National University R&DB Foundation
    Inventors: Tai Hyun Park, Seung Hun Hong, Hyun Seok Song, Hye Jun Jin, Sae Ryun Ahn
  • Patent number: 10894814
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 19, 2021
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth William Walker
  • Patent number: 10888626
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: January 12, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Patent number: 10889835
    Abstract: This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Anastasios Melis, Cinzia Formighieri
  • Patent number: 10889830
    Abstract: The subject invention concerns new classes of insecticidally-active proteins and the polynucleotide sequences which encode these proteins. More specifically, insecticidal proteins of approximately 12-24 kDa and of approximately 12-14 kDa are used for controlling corn rootworms. The subject invention includes methods and transgenic plants for controlling Western Corn Rootworm and other coleopteran insects.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 12, 2021
    Assignee: DOW AGROSCIENCES LLC
    Inventors: Kenneth E. Narva, Huarong Li, Sek Yee Tan, Tao Xu, Timothy D. Hey, Vimbai Chikwana, Sarah E. Worden
  • Patent number: 10889742
    Abstract: The present disclosure relates to the technical field of water-based drilling fluid, in particular to a modified polyhistidine suitable for being used as a supramolecular shale inhibitor, a method of preparing the same, and its application in water-based drilling fluids. The modified polyhistidine has a histidine polymerization main chain comprising a structural unit, which is represented by Formula (1) and attached with a modifying group, and the histidine polymerization main chain has a histidine polymerization degree of 6-9. The modified polyhistidine provided by the present disclosure is a degradable biological material and has the advantage of environmental friendliness; when the modified polyhistidine is used as a shale inhibitor, it can take advantage of its supermolecular property to effectively inhibit the hydration expansion of montmorillonite which is the most important expansion mineral in shale, and exhibits excellent inhibition effect and desirable temperature resistance.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: January 12, 2021
    Assignees: CHINA UNIVERSITY OF PETROLEUM (BEIJING), BEIJING SHIDA BOCHENG TECHNOLOGY CO., LTD
    Inventors: Guancheng Jiang, Yinbo He, Lili Yang, Kai Wang, Tengfei Dong, Xiaohu Quan, Kaixiao Cui, He Shi
  • Patent number: 10870692
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: December 22, 2020
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 10844392
    Abstract: This document provides materials and methods for producing endostatin fusion polypeptides having anti-fibrotic activity. For example, provided herein are fusion polypeptides having an IgG Fc domain and a portion of human endostatin that can form high molecular weight multimers, as well as methods for producing such fusion polypeptides in plant cells.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 24, 2020
    Assignees: iBio, Inc., MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, NOVICI BIOTECH LLC
    Inventors: Carol Feghali-Bostwick, Terence E Ryan, Hal S. Padgett, Matthew McGee
  • Patent number: 10829554
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 10, 2020
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Patent number: 10828262
    Abstract: The present invention provides a method of preparing biomembrane, closed structure with biomembrane characteristics or cellular compartment, comprising the following steps: 1), acquire biological cells from natural tissues or natural biological species; 2), culture the cells obtained in step 1) massively in an appropriate environment; 3), acquire the lysates of cells in step 2), and extracting the biomembrane, closed structure with biomembrane characteristics and cellular compartment through differential centrifugation, density gradient centrifugation or dual-phase extraction individually or a combination of two methods or a combination of three methods thereof. The membrane is a natural biomembrane, closed structure with biomembrane characteristics and cellular compartment, which can be used for package of active ingredients in various fields.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: November 10, 2020
    Assignee: Hangzhou UMotor Biotech Co., LTD.
    Inventors: Ying Gao, Yanming Wang, Jianliang Wei, Minzi Wang, Ye Cheng, Mingzhou Zhang, Liying Ye
  • Patent number: 10821141
    Abstract: Recombinant herpes simplex virus (HSV)-1 capable of selectively replicating in alternative lengthening of telomeres (ALT)-dependent tumor cells are described. The recombinant HSV-1 are ICP0-deficient, such as by complete deletion of the ICP0 gene, or mutation of the ICP0 gene sufficient to diminish or eliminate E3 ubiquitin ligase activity of ICP0. In some cases, the recombinant HSV-1 further include additional gene deletions or mutations, such as those that render the virus glycoprotein C (gC) deficient, or include a heterologous gene, such as a gene encoding an immunostimulatory molecule. Methods of treating ALT-dependent cancer, and methods of selectively killing ALT-dependent tumor cells are also described.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 3, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Jason DeHart
  • Patent number: 10822391
    Abstract: Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: November 3, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Abraham Scaria, Gary White
  • Patent number: 10824990
    Abstract: A merchandise management device is provided for a store having a first display location where a number of first merchandise is to be displayed and a second display location where a number of second merchandise is to be displayed. The merchandise management device includes cameras positioned to capture a first image indicating how many of the first merchandise is displayed at the first location and a second image indicating how many of the second merchandise is displayed at the second location, and a processor configured to detect whether or not there is a change in a displayed number of the first merchandise and a displayed number of the second merchandise, and for each merchandise item for which the change is detected, determine a degree and a direction of change and generate a replenishment alert if the degree of change in a decreasing direction is greater than a threshold.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: November 3, 2020
    Assignee: TOSHIBA TEC KABUSHIKI KAISHA
    Inventor: Xiaozhou Wang
  • Patent number: 10815489
    Abstract: The present invention provides modified aminoacyl-tRNA synthetases (ARSs) having increased reactivity with N-methyl amino acids compared to natural aminoacyl-tRNA synthetases. The modified aminoacyl-tRNA synthetases according to the present invention can aminoacylate tRNAs with their corresponding N-methyl-substituted amino acids such as N-methyl-phenylalanine, N-methyl-valine, N-methyl-serine, N-methyl-threonine, N-methyl-tryptophan, and N-methyl-leucine more efficiently than natural aminoacyl-tRNA synthetases. The present invention enables a more efficient production of polypeptides containing N-methyl amino acids.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 27, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsushi Ohta, Yusuke Yamagishi, Atsushi Matsuo
  • Patent number: 10815455
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 27, 2020
    Assignee: Vaximm AG
    Inventors: Heinz Lubenau, Marco Springer
  • Patent number: 10806776
    Abstract: A vaccine comprising Calnexin fragment and a method of using the vaccine to immunize a patient against fungi are disclosed. The Calnexin fragment may be either a full-length native version or a functionally equivalent version of full-length Calnexin.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 20, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Bruce Steven Klein, Theodore Tristan Brandhorst, Thomas Sullivan, Marcel Wuethrich
  • Patent number: 10808272
    Abstract: Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content. Furthermore, provided is a medium composition, for regulating the antibody sugar chain content, the medium composition including glycerol as an additive for regulating the antibody sugar chain content.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: October 20, 2020
    Assignee: Prestige Biopharma PTE. LTD.
    Inventors: Jae Young Chang, Eun Ho Hwang, Yong Jin Kim, Won Kyum Kim, Sang Kyung Park, Jun Yong Park, Kyo Eun Ahn, Yong Ho Ahn, Ji Yong Yoon, Jung Woo Lee
  • Patent number: 10808236
    Abstract: The present invention relates to a novel protcolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 20, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventor: Andreas Rummel
  • Patent number: 10801038
    Abstract: Provided herein are opto-genetic systems, cells, and methods thereof for modulating and regulating genetic expression in transiently active cells. The technologies described herein provide a transformative genetic regulatory tool for in vivo applications, which broadly spans a variety of disciplines, including behavioral, cognitive, and systems neuroscience.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 13, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: Adam Tyler Vogel
  • Patent number: 10793883
    Abstract: A recombinant strain of F. diplosiphon was made by transforming wild type F. diplosiphon with a pGEM-7Zf (+) plasmid containing sterol desaturase gene (SD) via electroporation. The recombinant strain was designated B481-SD and overexpressed the sterol desaturase gene to result in enhanced lipid production. Selection made on NaCl enabled growth of the transformant to thrive up to 50 g L?1 NaCl. This strain was designated B481-SDH.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 6, 2020
    Assignee: Morgan State University
    Inventors: Viji Sitther, Somayeh Gharaie Fathabad
  • Patent number: 10793621
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 6, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Patent number: 10787488
    Abstract: Photosynthetic microorganisms with broadened light absorption capability and increased photosynthetic activity are described. Broadened light absorption is achieved by modifying the microorganism to utilize non-native bilins. Increased photosynthetic activity results from the broadened light absorption and can also result from a decrease in self-shading. The microorganisms include Cyanobacteria, including modified Cyanobacteria.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 29, 2020
    Assignees: LUMEN BIOSCIENCE, INC., RELIANCE HOLDING USA, INC.
    Inventors: James Roberts, David M. Doughty
  • Patent number: 10786438
    Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 29, 2020
    Assignee: Krystal Biotech, Inc.
    Inventors: Suma Krishnan, Trevor Parry, Pooja Agarwal
  • Patent number: 10787505
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 29, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger